Evidence map›Paper›PMID 34593219›Full record

ReviewSeminars in oncology2021

The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review.

Yoanna S Pumpalova, Leslie Segall, Richard Felli, Gauri Bhatkhande, Judith S Jacobson, Alfred I Neugut

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yoanna S PumpalovaDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York NY. Electronic address: yp2184@cumc.columbia.edu.
Leslie SegallDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York NY.
Richard FelliRutgers New Jersey Medical School, Newark, NJ.
Gauri BhatkhandeDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York NY.
Judith S JacobsonDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York NY; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York NY.
Alfred I NeugutDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York NY; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York NY; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York NY.
Columbia University · USRutgers, The State University of New Jersey · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Training Program in Cancer-related Population SciencesT32CA094061 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NEUGUT, ALFRED I., TERRY, MARY BETH · 2017 to 2021
$1.1M
NCI NIH HHS P30 CA013696NCI NIH HHS T32 CA094061
6 · The paper itself

Abstract

backgroundCancer is the leading cause of morbidity and mortality among people living with HIV (PLWH). Although gastrointestinal (GI) cancers are not associated with HIV, their incidence is rising among PLWH, and yet little is known about how HIV affects their presentation, treatment and outcomes.

methodsWe searched PubMed using "HIV" and "cancer", "esophageal cancer", "gastric cancer", "stomach cancer", "gastroesophageal cancer", "colorectal cancer", "colon cancer", or "rectal cancer". We included studies comparing an HIV-positive group (n ≥ 4) to an HIV-negative group, with respect to clinical presentation, treatment, or mortality of GI cancers.

resultsOf 18 articles that met inclusion criteria, 17 were retrospective, and 13 described patients in the United States. At diagnosis with colorectal, but not pancreatic, gastric, or esophageal cancer, PLWH were younger than patients who were HIV-negative. PLWH did not present with more advanced stage GI cancers than patients who were HIV-negative. Compared to HIV-negative controls, PLWH with colorectal cancer had a higher proportion of right-sided versus left-sided colon cancers and a higher proportion of rectal versus colon cancers. Among patients diagnosed with colorectal or pancreatic cancer, PLWH were less likely to receive cancer treatment than other patients; no studies examined the association of HIV status with treatment for esophageal or gastric cancer. PLWH with GI malignancies had higher all-cause mortality compared to patients who were HIV-negative, but evidence for cancer-specific mortality was limited and mixed.

conclusionPLWH with GI malignancies were less likely to receive cancer treatment and had higher all-cause mortality than patients who were HIV-negative. Most of the studies focused on colorectal cancer; more studies are needed in pancreatic, gastric and esophageal cancer. Future studies should investigate the effects of HIV on cancer-specific mortality, especially among patients in low- and middle-income countries, including those with high HIV prevalence.

Indexed as

Colonic NeoplasmsEsophageal NeoplasmsGastrointestinal NeoplasmsHIV InfectionsStomach NeoplasmsHumansRetrospective StudiesUnited StatesAIDSdisparitiesgastrointestinal cancerHIV

Identifiers

PMID34593219
PMCPMC8578399
OpenAlexW3199474356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.